Open AccessProlonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
Author(s) -
Nava Zisapel,
Lemoine,
Doron Garfinkel,
Moshe Laudon,
Nir
Publication year - 2011
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s23036
Subject(s) - medicine , discontinuation , insomnia , melatonin , placebo , adverse effect , psychiatry , alternative medicine , pathology
Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month efficacy and safety of PRM in insomnia patients aged 18-80 and lack of withdrawal and rebound symptoms upon discontinuation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom